Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Blood (2023) 142 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2023-181151

Published: 2023

Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 6498–6500.

https://doi.org/10.1182/blood-2022-163683

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Maro Ohanian, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2021-150049

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2021-148827

Published: 2021

Journal Articles

Multi-Omics of Aurora Inhibition Induced Polyploidy Reveals Mechanisms of Disease Relapse in MYC/BCL2-Addicted High Grade B-Cell Lymphoma

Shariful Islam, Andrew Paek, PhD, Michael Hammer, PhD, Savithri Rangarajan, PhD, Robert Ruijtenbeek, PhD, Laurence Cooke, MS, Eric Weterings, PhD, Daruka Mahadevan, MD PhD

Blood (2018) 132 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2018-99-109975

Published: 2018

Journal Articles

RX-3117, a Novel Nucleoside Analog Targeting UCK2 Is Active Alone and Synergistic with Ibrutinib and Bendamustine in ABC and DH/DP- Diffuse Large B-Cell Lymphoma

Shariful Islam, Umar Zahid, MD, Laurence Cooke, MS, Young Bok Lee, Deog Joong Kim, Ely Benaim, MD, Daruka Mahadevan, MD PhD

Blood (2017) 130 (Supplement 1): 5196.

https://doi.org/10.1182/blood.V130.Suppl_1.5196.5196

Published: 2017

Journal Articles

Phase II/1b Trial of Ibrutinib Plus Prednisone and Rituximab Induction Followed By Venetoclax Plus Ibrutinib Maintenance in Newly Diagnosed High-Risk Chronic Lymphocytic Leukemia

Soyoung Park, MD, Lisa Davis, PharmD, Paul Hsu, PhD, Daniel Persky, MD, Daruka Mahadevan, MD PhD

Blood (2017) 130 (Supplement 1): 5351.

https://doi.org/10.1182/blood.V130.Suppl_1.5351.5351

Published: 2017

Journal Articles

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Abhijeet Kumar, MD, Jose Guillen-Rodriguez, Jonathan H. Schatz, MD, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, MD, Faiz Anwer, MD, Daruka Mahadevan, MD PhD, Daniel O. Persky, MD, Soham D. Puvvada, MD

Blood (2016) 128 (22): 1790.

https://doi.org/10.1182/blood.V128.22.1790.1790

Published: 2016

Journal Articles

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

Shariful Islam, MS, Wenqing Qi, PhD, Carla Morales, B.S., Laurence Cooke, M.S., Manjari Pandey, MD, Catherine M. Spier, MD, Daruka Mahadevan, MD PhD

Blood (2016) 128 (22): 5397.

https://doi.org/10.1182/blood.V128.22.5397.5397

Published: 2016

Journal Articles

A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia

Daruka Mahadevan, MD PhD, Emily K. Pauli, BMBS, PharmD, Kathy Cutter, RN, BSN, Lee Ann Dietz, RN, Peter Sportelli, Hari P. Miskin, MS, Marshall T. Schreeder, MD

Blood (2015) 126 (23): 2942.

https://doi.org/10.1182/blood.V126.23.2942.2942

Published: 2015

Journal Articles

Aurora Plus PI3K Inhibition Abrogates PD-L1 Induction in Peripheral T-Cell Non-Hodgkin Lymphoma

Daruka Mahadevan, MD PhD, Eric Vick, PhD, Bryan Huber, MD, Carla Morales, B.S., Laurence Cooke, M.S., Catherine M. Spier, MD, Wenqing Qi, PhD

Blood (2015) 126 (23): 1560.

https://doi.org/10.1182/blood.V126.23.1560.1560

Published: 2015

Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Kathryn Kolibaba, MD, John M. Burke, MD, Heather D. Brooks, MD BS, BA, Daruka Mahadevan, MD PhD, Jason Melear, MD, Charles M. Farber, MD PhD, Suzanne R. Fanning, DO, Marshall T. Schreeder, MD, Ralph V. Boccia, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3980.

https://doi.org/10.1182/blood.V126.23.3980.3980

Published: 2015

Journal Articles

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin

Kelly Zullo, MS, Yige Guo, PhD, Laurence Cooke, B.A., Xavier Jirau Serrano, BS, Michael Mangone, PhD, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Daruka Mahadevan, MD PhD, Owen A. O'Connor, MD PhD

Blood (2014) 124 (21): 4493.

https://doi.org/10.1182/blood.V124.21.4493.4493

Published: 2014

Journal Articles

Novel Targeted Combination Therapies for Peripheral T-Cell Lymphoma

Daruka Mahadevan, MD PhD, Carla Morales, BS, Bryan D. Huber, MD, Mansoor Ul Haq, MD, Catherine M. Spier, MD, Laurence S. Cooke, MS, Wenqing Qi, PhD

Blood (2014) 124 (21): 4494.

https://doi.org/10.1182/blood.V124.21.4494.4494

Published: 2014

Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

Jeff P. Sharman, MD, Charles M. Farber, MD PhD, Daruka Mahadevan, MD PhD, Marshall T. Schreeder, MD, Heather D. Brooks, MD, Kathryn S. Kolibaba, MD, Suzanne R. Fanning, DO, Leonard M. Klein, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Daniel R. Greenwald, MD

Blood (2014) 124 (21): 4679.

https://doi.org/10.1182/blood.V124.21.4679.4679

Published: 2014

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD, Wael A. Harb, MD, Brian T. Hill, MD, PhD, Janice Gabrilove, MD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, MPH, Paul M. Barr, MD, James M. Foran, MD, Thomas P. Miller, MD, Jan A. Burger, MD, PhD, Kevin R. Kelly, MD, PhD, Daruka Mahadevan, MD, PhD, Shuo Ma, MD, PhD, Evelyn Barnett, Jeffrey Marine, Pilar Nava-Parada, Ada Azaryan, Jay Mei, MD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 1630.

https://doi.org/10.1182/blood.V122.21.1630.1630

Published: 2013

Journal Articles

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Curative of Double Hit Diffuse Large B-Cell Lymphoma in Mice

Daruka Mahadevan, MD, PhD

Blood (2012) 120 (21): 159.

https://doi.org/10.1182/blood.V120.21.159.159

Published: 2012

Journal Articles

Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.

Marie O'Farrell, PhD, Richard Ventura, Albert Tai, Jeffrey W Tyner, PhD, Marc M Loriaux, MD, PhD, Daruka Mahadevan, MD, PhD, Carla Morales, S. David Brown, David J Matthews, PhD

Blood (2012) 120 (21): 2907.

https://doi.org/10.1182/blood.V120.21.2907.2907

Published: 2012

Journal Articles

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Jonathan Friedberg, MD, Daruka Mahadevan, MD, PhD, JungAh Jung, PhD, Daniel O. Persky, MD, Izidore S Lossos, MD, Hadi Danaee, SD, Xiaofei Zhou, PhD, E Jane Leonard, Steven H. Bernstein

Blood (2011) 118 (21): 95.

https://doi.org/10.1182/blood.V118.21.95.95

Published: 2011

NARROW

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Multi-Omics of Aurora Inhibition Induced Polyploidy Reveals Mechanisms of Disease Relapse in MYC/BCL2-Addicted High Grade B-Cell Lymphoma

RX-3117, a Novel Nucleoside Analog Targeting UCK2 Is Active Alone and Synergistic with Ibrutinib and Bendamustine in ABC and DH/DP- Diffuse Large B-Cell Lymphoma

Phase II/1b Trial of Ibrutinib Plus Prednisone and Rituximab Induction Followed By Venetoclax Plus Ibrutinib Maintenance in Newly Diagnosed High-Risk Chronic Lymphocytic Leukemia

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia

Aurora Plus PI3K Inhibition Abrogates PD-L1 Induction in Peripheral T-Cell Non-Hodgkin Lymphoma

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin

Novel Targeted Combination Therapies for Peripheral T-Cell Lymphoma

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Curative of Double Hit Diffuse Large B-Cell Lymphoma in Mice

Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only